Tuesday, October 20, 2026, 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Roche.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 29, 2026, 1 PM-2 PM ET
Hear an expert discuss the evolving role of PD-L1 testing in HNSCC and ovarian cancer.
Webinar presenter Georgios Deftereos, MD, Professor of Pathology, Associate Director of the Clinical Cancer Genomics Laboratory, Director of Molecular Cytopathology, University of California, San Francisco
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Agilent.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
July 2026—Roche introduced the Cobas MPX-E assay, a qualitative in vitro test for the detection and discrimination of HIV 1 and 2 and hepatitis C, B, and E viruses, in countries accepting the CE mark. By identifying these pathogens simultaneously, the assay aims to help laboratories streamline their operations while enhancing the safety of blood and blood products for patients.
July 2026—Tempus AI has launched the ArteraAI Prostate test (mHSPC) for clinical use. The test uses multimodal artificial intelligence to provide insights for personalized care for patients with metastatic hormone-sensitive prostate cancer.
July 2026—Streck has launched MDx-Chex for Chlamydia trachomatis, Neisseria gonorrhoeae, and Trichomonas vaginalis and MDx-Chex for MVP (multiplex vaginal panel) for research use only.
July 2026—QuidelOrtho has completed the acquisition of Lex Diagnostics for about $100 million in cash. The acquisition follows the FDA 510(k) clearance and CLIA waiver of the Lex Velo molecular diagnostics platform in February.
July 2026—Grifols launched at the International Society of Blood Transfusion Congress (Kuala Lumpur, Malaysia, June 20–24) the Evanzys IH, a modular, fully automated, track-enabled system designed to streamline operations and reduce manual intervention in immunohematology sample processing.
June 2026—Qiagen has released the CE-IVDR-certified QIAstat-Dx BCID GPF Plus AMR panel.
June 2026—Anchor Molecular launched its BCR-ABL1 control panels designed to support laboratories in monitoring the performance of the quantitative detection of BCR-ABL1 translocation mRNA transcripts.
June 2026—Bruker announced at ESCMID Global 2026 (Munich, April 17–21) portfolio enhancements to its MALDI Biotyper workflow. The proprietary MBT Easy T kit, available for research use only or CE-IVD marked under the EU IVDR, is designed to simplify and standardize sample transfer steps to MALDI target plates. It includes ready-to-use reagents and applicators, supporting up to 2,000 samples, and features room-temperature storage.
June 2026—Artera has been granted the CE mark under the European Union in vitro diagnostic regulation for its ArteraAI Prostate Biopsy and ArteraAI Breast Cancer assays.
June 2026—Streck launched CD-Chex Daily, a ready-to-use quality control for flow cytometry laboratories. It provides coverage across 51 assayed, research-use-only markers in a single vial, with markers spanning surface, intracellular, and leukocyte scatter populations, including CD200, TRBC1, cMPO, CD27, CD36, CD81, cCD79a, CD79b, cKappa, cLambda, and others.
